WeVote
Log In

Bill

Bill

SR 1302

Tardive Dyskinesia Awareness Week

2025 Regular Session Introduced by Ana Maria Rodriguez

Designates an annual Tardive Dyskinesia Awareness Week to educate patients and providers, promote TD screening for long-term antipsychotic users, and share resources.

Adopted
#(adopted)
0
WeVote Research Nonpartisan
Bill Summary · SR 1302

Summary of SR 1302 — Tardive Dyskinesia Awareness Week

Overview

  • Bill type: Senate Resolution (non-binding)
  • Title: Tardive Dyskinesia Awareness Week
  • Status: Adopted
  • Introduced: February 26, 2025
  • Legislative actions: Filed (Feb 26, 2025); Introduced (Mar 27, 2025); Read 2nd time (Mar 27, 2025); Adopted (Mar 27, 2025)

Purpose and Intent

SR 1302 designates a period each year as Tardive Dyskinesia Awareness Week to raise public awareness about tardive dyskinesia (TD). The resolution aims to educate patients, families, and healthcare professionals about TD, promote early recognition of symptoms, and emphasize support for individuals living with the condition.

Key Provisions

  • Designation: Establishes annual Tardive Dyskinesia Awareness Week. (Specific dates are determined by the resolution or designated by the legislature in practice.)
  • Awareness Activities: Encourages government agencies, healthcare organizations, schools, and community groups to observe the week through educational events, public information campaigns, and community outreach.
  • Education for Providers: Urges healthcare professionals to prioritize screening for TD symptoms in patients who have long-term exposure to certain antipsychotic medications, and to share information about risk factors and available resources.
  • Public Resources: Encourages dissemination of information about TD signs, treatment options, and support resources to the public.
  • Advocacy and Support: Expresses support for individuals affected by TD and their families, and promotes collaboration with patient advocacy groups and medical associations.

Impact and Stakeholders

  • Impact: Being a non-binding resolution, SR 1302 does not create legal requirements or allocate funds. Its primary impact is ceremonial recognition and the potential to influence awareness and education efforts across public and private sectors.
  • Interested Parties: Patients with tardive dyskinesia and their families, healthcare providers (neurology, psychiatry, primary care, pharmacology), medical associations, patient advocacy organizations, educational institutions, and state health agencies.

Procedural and Timeline Notes

  • The resolution was filed on February 26, 2025, then introduced and subsequently adopted on March 27, 2025. As a resolution, it typically takes effect upon adoption and does not amend statutes or authorize new spending.

Context on Tardive Dyskinesia (TD)

TD is a movement disorder often associated with long-term use of certain antipsychotic medications. Awareness efforts focus on recognizing early symptoms (involuntary facial or limb movements), informing patients about risks, and encouraging discussions with healthcare providers about monitoring and treatment options.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.